| 刘 睿,吕雨桐,姜翠红,王高兴,赵志正.艾迪注射液联合XELOX方案对晚期结直肠癌患者Th1/Th2免疫平衡和血清肿瘤标志物的影响[J].现代生物医学进展英文版,2022,(5):872-875. |
| 艾迪注射液联合XELOX方案对晚期结直肠癌患者Th1/Th2免疫平衡和血清肿瘤标志物的影响 |
| Effects of Aidi Injection Combined with XELOX Regimen on Th1/Th2 Immune Balance and Serum Tumor Markers in Patients with Advanced Colorectal Cancer |
| Received:September 06, 2021 Revised:September 29, 2021 |
| DOI：10.13241/j.cnki.pmb.2022.05.015 |
| 中文关键词: 艾迪注射液 XELOX方案 晚期 结直肠癌 Th1/Th2免疫平衡 肿瘤标志物 |
| 英文关键词: Aidi injection XELOX regimen Advanced Colorectal cancer Th1/Th2 immune balance Tumor markers |
| 基金项目:国家自然科学基金资助项目（81703918）；中国中医科学院广安门医院南区院级科研基金项目（Y2020-03） |
|
| Hits: 778 |
| Download times: 447 |
| 中文摘要: |
| 摘要 目的：探讨艾迪注射液联合卡培他滨和奥沙利铂方案（XELOX方案）对晚期结直肠癌患者Th1/Th2免疫平衡和血清肿瘤标志物的影响。方法：病例选取自我院2018年7月~2021年6月期间收治的晚期结直肠癌患者80例，采用计算机随机生成的方式分为对照组（XELOX方案）和研究组（艾迪注射液联合XELOX方案），各为40例。对比两组疗效、Karnofsky （KPS）评分、Th1/Th2免疫平衡和血清肿瘤标志物，观察两组不良反应发生率。结果：研究组的客观缓解率 （ORR）、疾病控制率（DCR）高于对照组（P<0.05）。两组治疗后KPS评分升高，且研究组高于对照组（P<0.05）。两组治疗后Th1、干扰素-γ（IFN-γ）、Th1/Th2降低，但研究组高于对照组（P<0.05）。两组治疗后Th2、白细胞介素-10（IL-10）升高，但研究组低于对照组（P<0.05）。两组治疗后癌胚抗原(CEA)、糖类抗原199 ( CA199) 、糖类抗原724( CA724)下降，且研究组低于对照组（P<0.05）。研究组不良反应发生率低于对照组（P<0.05）。结论：艾迪注射液联合XELOX方案治疗晚期结直肠癌患者，可在一定程度上阻止肿瘤疾病进展，减轻免疫抑制，提高近期疗效，减少因药物副作用引起的不良反应，进而改善患者生活质量。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Aidi injection combined with capecitabine and oxaliplatin regimen (XELOX regimen) on Th1/Th2 immune balance and serum tumor markers in patients with advanced colorectal cancer. Methods: 80 patients with advanced colorectal cancer who were treated in our hospital from July 2018 to June 2021 were selected, and they were randomly divided into control group (XELOX scheme) and study group (Aidi injection combined with XELOX scheme), with 40 cases each. The efficacy, Karnofsky (KPS) score, Th1/Th2 immune balance and serum tumor markers were compared between the two groups, and the incidence of adverse reactions was observed. Results: The objective remission rate(ORR) and disease control rate(DCR) in the study group were higher than those in the control group(P<0.05). The KPS score of the two groups after treatment increased, and the study group was higher than the control group (P<0.05). Th1, interferon-γ (IFN-γ) and Th1/Th2 in the two groups decreased, but the study group was higher than the control group(P<0.05). After treatment, Th2 and interleukin-10(IL-10) in both groups increased, but the study group was lower the control group (P<0.05). Carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) and carbohydrate antigen 724 (CA724) in the two groups decreased, and the study group was lower than the control group(P<0.05). The incidence of adverse reactions in the study group was lower than that in the control group(P<0.05). Conclusion: Aidi injection combined with XELOX regimen in the treatment of patients with advanced colorectal cancer can prevent tumor disease progression, reduce immunosuppression, improve short-term curative effect, reduce adverse reactions caused by drug side effects, and then improve the quality of life of patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
